133 related articles for article (PubMed ID: 20227234)
1. [Visceral leishmaniasis in immunocompetent adult with severe sepsis].
Ezzouine H; Charra B; Benslama A; Motaouakkil S
Ann Fr Anesth Reanim; 2010 Mar; 29(3):255-6. PubMed ID: 20227234
[No Abstract] [Full Text] [Related]
2. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
3. Visceral leishmaniasis treatment, Italy.
Gradoni L; Gramiccia M; Scalone A
Emerg Infect Dis; 2003 Dec; 9(12):1617-20. PubMed ID: 14720406
[TBL] [Abstract][Full Text] [Related]
4. [Visceral leishmaniasis in an immunocompetent subject, acquired in the Pyrenees region].
Malvy D; Djossou F; Ibanez C; Vatan R; Longy-Boursier M; Le Bras M
Presse Med; 2006 Jun; 35(6 Pt 1):987-8. PubMed ID: 16783261
[TBL] [Abstract][Full Text] [Related]
5. [Visceral leishmaniasis with cardiac affectation in an immunocompetent patient].
Puerto-Alonso JL; Molina-Ruano FJ; Gómez-Soto F; Gómez-Rodríguez F
Med Clin (Barc); 2006 Oct; 127(13):519. PubMed ID: 17043012
[No Abstract] [Full Text] [Related]
6. [Isolated laringeal leishmaniasis and bone marrow culture (reply)].
Benítez MD; Miranda C; Navarro JM; Morillas F; Martín J; de La Rosa M
Enferm Infecc Microbiol Clin; 2002 Mar; 20(3):133-4. PubMed ID: 11904090
[No Abstract] [Full Text] [Related]
7. [Visceral leishmaniasis with benign course in a patient infected with human immunodeficiency virus].
Ribelles N; Casals A; Vallés J; Clotet B
Med Clin (Barc); 1989 May; 92(17):679. PubMed ID: 2747338
[No Abstract] [Full Text] [Related]
8. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
[TBL] [Abstract][Full Text] [Related]
10. Oral leishmaniasis in an HIV-positive patient caused by two different zymodemes of Leishmania infantum.
Cortés P; Cardeñosa N; Romaní J; Gállego M; Muñoz C; Barrio JL; Riera C; Portús M
Trans R Soc Trop Med Hyg; 1997; 91(4):438-9. PubMed ID: 9373646
[No Abstract] [Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis caused by Leishmania infantum in an immunocompetent patient.
Sánchez-Albisua B; Polimón I; Pérez-Tato B; Marinero S; Fernández-López P
Int J Dermatol; 2013 Jul; 52(7):897-9. PubMed ID: 23675968
[No Abstract] [Full Text] [Related]
12. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
Hakimi S; Rivière S; Del Giudice P; Dereure J; Le Quellec A
Dermatology; 2010; 220(1):63-5. PubMed ID: 19907139
[TBL] [Abstract][Full Text] [Related]
13. Mucosal leishmaniasis of the tongue caused by Leishmania infantum in an immunocompetent woman.
Pampín Franco A; Gamo Villegas R; Caro-Gutiérrez D; López-Estebaranz JL; Pinedo F
Int J Dermatol; 2015 Jan; 54(1):e39-41. PubMed ID: 25312835
[No Abstract] [Full Text] [Related]
14. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
16. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis.
Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM
Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691
[TBL] [Abstract][Full Text] [Related]
17. Lingual leishmaniasis complicating visceral disease.
Mazumder SA; Pandey S; Brewer SC; Baselski VS; Weina PJ; Land MA; Fleckenstein JM
J Travel Med; 2010; 17(3):212-4. PubMed ID: 20536896
[TBL] [Abstract][Full Text] [Related]
18. Our experiences in visceral leishmaniasis therapy.
Titone L; Scarlata F; Cascio A; Giordano S; Mancuso G
J Chemother; 1989 Jul; 1(4 Suppl):960-1. PubMed ID: 16312722
[No Abstract] [Full Text] [Related]
19. Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis.
Disch J; Oliveira MC; Orsini M; Rabello A
Acta Trop; 2004; 92(3):279-83. PubMed ID: 15533299
[TBL] [Abstract][Full Text] [Related]
20. Mediterranean visceral leishmaniasis in pregnancy.
Gradoni L; Gaeta GB; Pellizzer G; Maisto A; Scalone A
Scand J Infect Dis; 1994; 26(5):627-9. PubMed ID: 7855563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
